Guest guest Posted March 24, 2008 Report Share Posted March 24, 2008 The purpose of this clinical research study is to determine if two doses of the investigational drug nilotinib are safe and effective when compared to imatinib mesylate (Gleevec®) in newly diagnosed patients with Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML). An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA). Newly diagnosed Philadelphia chromosome positive CML Study - CAMN107A2303 http://tinyurl.com/2avetp There is a questionaire to fill out first to see if you are eligible and you will be routed to the nearest center according to your zip code. The duration of this trial is 5 years. A Novartis Glossary of Terms: http://tinyurl.com/27xw42 Blood level testing can help identify the potential cause of suboptimal response to oral first-line therapy. http://www.cmlalliance.com/cml-alliance-testing.jsp Blessings, Lottie Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.